Rinvoq 15 mg/1
Upadacitinib · TABLET, EXTENDED RELEASE · AbbVie Inc.
No Recall History
Plain English
Rinvoq is a tablet, extended release containing upadacitinib at 15 mg/1, taken oral. Manufactured by AbbVie Inc..
Key Facts
- Brand Name
- Rinvoq
- Generic Name
- Upadacitinib
- NDC Code (Product)
0074-2306- Manufacturer
- AbbVie Inc.
- Strength
- 15 mg/1
- Dosage Form
- TABLET, EXTENDED RELEASE
- Route
- ORAL
- Marketing Status
- Application #
- NDA211675
- Drug Class
- Janus Kinase Inhibitor [EPC]
- Marketing Start
- 08/16/2019
Recall History
No Recall HistoryFrequently Asked Questions
What is Rinvoq used for?
Rinvoq contains Upadacitinib. It is a tablet, extended release taken oral. Consult your doctor for specific uses.
Is Rinvoq a controlled substance?
Rinvoq is not classified as a controlled substance by the DEA.
What is the generic name for Rinvoq?
The generic name for Rinvoq is Upadacitinib. There are no other listed brand versions of Upadacitinib.
What is the NDC code for Rinvoq 15 mg/1?
The NDC (National Drug Code) for Rinvoq 15 mg/1 is 0074-2306, listed by AbbVie Inc..
Other Rinvoq Dosages
Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.
Data from openFDA · Public domain (CC0 1.0)